Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects.

Nakov R, Gattu S, Wang J, Velinova M, Schaffar G, Skerjanec A.

Br J Clin Pharmacol. 2018 Dec;84(12):2790-2801. doi: 10.1111/bcp.13731. Epub 2018 Sep 28.

PMID:
30079636
2.

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.

Weir MR, Pergola PE, Agarwal R, Fink JC, Kopyt NP, Singh AK, Kumar J, Schmitt S, Schaffar G, Rudy A, McKay JP, Kanceva R.

Am J Nephrol. 2017;46(5):364-370. doi: 10.1159/000481736. Epub 2017 Oct 30.

PMID:
29084409
3.

State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015.

Poetzl J, Arlt I, von Richter O, Wöhling H, Afonso M, Schaffar G.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e130-e132. doi: 10.1111/jdv.14632. Epub 2017 Nov 6. No abstract available.

PMID:
29024096
4.

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients
.

Casadevall N, Dobronravov V, Eckardt KU, Ertürk S, Martynyuk L, Schmitt S, Schaffar G, Rudy A, Krendyukov A, Ode M.

Clin Nephrol. 2017 Oct;88(10):190-197. doi: 10.5414/CN109159.

6.

LIM-only protein 4 interacts directly with the repulsive guidance molecule A receptor Neogenin.

Schaffar G, Taniguchi J, Brodbeck T, Meyer AH, Schmidt M, Yamashita T, Mueller BK.

J Neurochem. 2008 Oct;107(2):418-31. doi: 10.1111/j.1471-4159.2008.05621.x. Epub 2008 Aug 12.

7.

Now we are talking sense! Functional approaches to novel nutraceuticals and cosmeceuticals.

Krohn M, Kleber A, Schaffar G, Dechert U, Eck J.

Biotechnol J. 2008 Oct;3(9-10):1147-56. doi: 10.1002/biot.200700204. No abstract available.

PMID:
18624347
8.

Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers.

Behrends C, Langer CA, Boteva R, Böttcher UM, Stemp MJ, Schaffar G, Rao BV, Giese A, Kretzschmar H, Siegers K, Hartl FU.

Mol Cell. 2006 Sep 15;23(6):887-97.

9.

The role of repulsive guidance molecules in the embryonic and adult vertebrate central nervous system.

Mueller BK, Yamashita T, Schaffar G, Mueller R.

Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1513-29. Review.

10.

Single particle detection and characterization of synuclein co-aggregation.

Giese A, Bader B, Bieschke J, Schaffar G, Odoy S, Kahle PJ, Haass C, Kretzschmar H.

Biochem Biophys Res Commun. 2005 Aug 12;333(4):1202-10.

PMID:
15978545
11.

Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.

Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, Sakahira H, Siegers K, Hayer-Hartl M, Hartl FU.

Mol Cell. 2004 Jul 2;15(1):95-105.

12.

Roles of molecular chaperones in protein misfolding diseases.

Barral JM, Broadley SA, Schaffar G, Hartl FU.

Semin Cell Dev Biol. 2004 Feb;15(1):17-29. Review.

PMID:
15036203
13.

Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils.

Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7841-6.

Supplemental Content

Loading ...
Support Center